Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04783428 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tumor-induced Osteomalacia Disease Monitoring Program

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv39
  2. Enrollment target: 22 to 23v38
  3. Study sites: 5 to 6v37
  4. Enrollment target: 21 to 22v36
  5. 7 versions Re-verified since Aug 15, 2023, no change to tracked fieldsv29-v35
Show 27 earlier versionsHide 27 earlier versions
  1. Enrollment target: 20 to 21v28
  2. Trial status: Recruiting to Active, Not Recruiting Site details revised at 5 of 5 sitesv27 Show 1 more changeShow less
    • Site details revised at 5 of 5 sites
  3. 3 versions Re-verified since Nov 21, 2022, no change to tracked fieldsv24-v26
  4. Study sites: 4 to 5v23
  5. 4 versions Re-verified since Jun 29, 2022, no change to tracked fieldsv19-v22
  6. Site details revised at 3 of 4 sitesv18
  7. 2 versions Re-verified since Apr 1, 2022, no change to tracked fieldsv16-v17
  8. Study sites: 5 to 4v15
  9. Study sites: 1 to 5 Start date changed from estimate of Jan 2022 to Jan 31, 2022v14 Show 1 more changeShow less
    • Start date changed from estimate of Jan 2022 to Jan 31, 2022
  10. Re-verified, no change to tracked fieldsv13
  11. Start date: Nov 2021 to Jan 2022 Primary and study completion dates: Dec 30, 2032 to Feb 28, 2032v12 Show 1 more changeShow less
    • Primary and study completion dates: Dec 30, 2032 to Feb 28, 2032
  12. Primary and study completion dates: Nov 30, 2032 to Dec 30, 2032v11
  13. Primary and study completion dates: Oct 2032 to Nov 30, 2032 Start date: Oct 2021 to Nov 2021v10 Show 1 more changeShow less
    • Start date: Oct 2021 to Nov 2021
  14. Re-verified, no change to tracked fieldsv9
  15. Primary and study completion dates: Feb 2031 to Oct 2032 Start date: Sep 2021 to Oct 2021v8 Show 1 more changeShow less
    • Start date: Sep 2021 to Oct 2021
  16. Start date: Jul 2021 to Sep 2021v7
  17. Re-verified, no change to tracked fieldsv6
  18. Start date: Jun 2021 to Jul 2021v5
  19. Start date: Apr 2021 to Jun 2021v4
  20. Trial status: Not Yet Recruiting to Recruiting Site details revisedv3 Show 1 more changeShow less
    • Site details revised
  21. Study sites: 0 to 1 Start date: Mar 2021 to Apr 2021v2 Show 1 more changeShow less
    • Start date: Mar 2021 to Apr 2021
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime in patients with TIO irrespective of their treatment status.
Trial Details
NCT Number NCT04783428
Lead Sponsor Ultragenyx Pharmaceutical Inc
Conditions Tumor-induced Osteomalacia (TIO)
Enrollment 23 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov